CXCR2 inhibition enables NASH-HCC immunotherapy

J Leslie, JBG Mackey, T Jamieson, E Ramon-Gil… - Gut, 2022 - gut.bmj.com
Objective Hepatocellular carcinoma (HCC) is increasingly associated with non-alcoholic
steatohepatitis (NASH). HCC immunotherapy offers great promise; however, recent data …

[HTML][HTML] Intratumoral heterogeneity and clonal evolution in liver cancer

B Losic, AJ Craig, C Villacorta-Martin… - Nature …, 2020 - nature.com
Clonal evolution of a tumor ecosystem depends on different selection pressures that are
principally immune and treatment mediated. We integrate RNA-seq, DNA sequencing, TCR …

[HTML][HTML] Polyphenols as potent epigenetics agents for cancer

P Rajendran, SA Abdelsalam, K Renu… - International journal of …, 2022 - mdpi.com
Human diseases such as cancer can be caused by aberrant epigenetic regulation.
Polyphenols play a major role in mammalian epigenome regulation through mechanisms …

Immunomodulatory effects of lenvatinib plus anti–programmed cell death protein 1 in mice and rationale for patient enrichment in hepatocellular carcinoma

L Torrens, C Montironi, M Puigvehí, A Mesropian… - …, 2021 - Wiley Online Library
Background and Aims Lenvatinib is an effective drug in advanced HCC. Its combination with
the anti‐PD1 (programmed cell death protein 1) immune checkpoint inhibitor …

[HTML][HTML] Pathophysiology and management of alcoholic liver disease: update 2016

F Stickel, C Datz, J Hampe, R Bataller - Gut and liver, 2017 - ncbi.nlm.nih.gov
Alcoholic liver disease (ALD) is a leading cause of cirrhosis, liver cancer, and acute and
chronic liver failure and as such causes significant morbidity and mortality. While alcohol …

Hepatocellular carcinoma: molecular mechanism, targeted therapy, and biomarkers

Y Wang, B Deng - Cancer and Metastasis Reviews, 2023 - Springer
Hepatocellular carcinoma (HCC) is a common malignancy and one of the leading causes of
cancer-related death. The biological process of HCC is complex, with multiple factors …

Liquid biopsy in the clinical management of hepatocellular carcinoma

J von Felden, T Garcia-Lezana, K Schulze, B Losic… - Gut, 2020 - gut.bmj.com
With increasing knowledge on molecular tumour information, precision oncology has
revolutionised the medical field over the past years. Liquid biopsy entails the analysis of …

[HTML][HTML] Comprehensive molecular and immunological characterization of hepatocellular carcinoma

S Shimada, K Mogushi, Y Akiyama, T Furuyama… - …, 2019 - thelancet.com
Background Hepatocellular carcinoma (HCC) is a heterogeneous disease with various
etiological factors, and ranks as the second leading cause of cancer-related mortality …

Palbociclib (PD-0332991), a selective CDK4/6 inhibitor, restricts tumour growth in preclinical models of hepatocellular carcinoma

J Bollard, V Miguela, MR De Galarreta, A Venkatesh… - Gut, 2017 - gut.bmj.com
Objective Advanced hepatocellular carcinoma (HCC) is a lethal malignancy with limited
treatment options. Palbociclib, a well-tolerated and selective CDK4/6 inhibitor, has shown …

Zebrafish: an important tool for liver disease research

W Goessling, KC Sadler - Gastroenterology, 2015 - Elsevier
As the incidence of hepatobiliary diseases increases, we must improve our understanding of
the molecular, cellular, and physiological factors that contribute to the pathogenesis of liver …